Innoviva, Inc.
$23.92
▼
-1.79%
2026-04-21 07:33:00
www.inva.com
NMS: INVA
Explore Innoviva, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$1.77 B
Current Price
$23.92
52W High / Low
$25.14 / $16.52
Stock P/E
6.53
Book Value
$15.71
Dividend Yield
—
ROCE
10.33%
ROE
29.09%
Face Value
—
EPS
$3.3
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
159
Beta
0.4
Debt / Equity
28.24
Current Ratio
14.64
Quick Ratio
13.85
Forward P/E
10.75
Price / Sales
4.31
Enterprise Value
$1.52 B
EV / EBITDA
7.82
EV / Revenue
3.71
Rating
Buy
Target Price
$33.2
EPS Forecast (FY)
—
Pros
- Healthy return on equity.
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Strong operating margin profile.
- Net margin remains healthy.
- Valuation is not stretched on P/E basis.
Cons
- Some data points may be missing or delayed because the source is not an official exchange feed.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | DiaMedica Therapeutics Inc. | $6.56 | — | $369.1 M | — | -61.16% | -67.68% | $10.42 / $3.28 | $1.04 |
| 2. | Inovio Pharmaceuticals, Inc. | $1.18 | — | $96.69 M | — | -283.35% | -1.83% | $2.98 / $1.03 | $0.35 |
| 3. | Lineage Cell Therapeutics, Inc. | $1.65 | — | $410.99 M | — | -21.52% | -1.05% | $2.09 / $0.4 | $0.18 |
| 4. | PDS Biotechnology Corporation | $1.29 | — | $72 M | — | -150.13% | -2.44% | $1.92 / $0.51 | $-4.02 |
| 5. | Vanda Pharmaceuticals Inc. | $6.99 | — | $417.3 M | — | -43.97% | -50.93% | $9.94 / $3.81 | $5.54 |
| 6. | Krystal Biotech, Inc. | $276.4 | 40.42 | $8.11 B | — | 13.1% | 18.91% | $298.3 / $122.8 | $41.78 |
| 7. | Cibus, Inc. | $1.56 | — | $118.83 M | — | -23.41% | -2.21% | $4.19 / $1.09 | $0.4 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 114.61 M | 107.8 M | 100.28 M | 88.63 M | 91.81 M | — |
| Operating Profit | 38.99 M | 34.58 M | 48.75 M | 41.43 M | 43.14 M | — |
| Net Profit | 164.15 M | 89.91 M | 63.69 M | -46.58 M | 20.33 M | — |
| EPS in Rs | 2.22 | 1.21 | 0.86 | -0.63 | 0.27 | 0.02 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 411.33 M | 358.71 M | 310.46 M | 331.34 M |
| Operating Profit | 163.75 M | 166.87 M | 113.89 M | 207 M |
| Net Profit | 271.17 M | 23.39 M | 179.72 M | 213.92 M |
| EPS in Rs | 3.66 | 0.32 | 2.43 | 2.89 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 1.64 B | 1.3 B | 1.24 B | 1.23 B |
| Total Liabilities | 462.32 M | 609.9 M | 568.55 M | 665.71 M |
| Equity | 1.17 B | 691.16 M | 674.96 M | 565.79 M |
| Current Assets | 727.51 M | 554.31 M | 344.22 M | 443.51 M |
| Current Liabilities | 49.7 M | 236.08 M | 38.13 M | 134.97 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | 196.93 M | 188.69 M | 141.06 M | 201.73 M |
| Investing CF | 40.5 M | -63.79 M | -66.76 M | -56.63 M |
| Financing CF | 8.55 M | -13.45 M | -171.84 M | -55.57 M |
| Free CF | 186.43 M | 184.42 M | 140.65 M | 201.66 M |
| Capex | -10.5 M | -4.27 M | -0.41 M | -0.07 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | 15.54% | -6.3% | — | — |
| Earnings Growth % | -86.98% | -15.99% | — | — |
| Profit Margin % | 6.52% | 57.89% | 64.56% | — |
| Operating Margin % | 46.52% | 36.68% | 62.47% | — |
| Gross Margin % | 89.8% | 86.27% | 95.84% | — |
| EBITDA Margin % | 23.84% | 75.71% | 93.05% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.